CR10225A - "compuestos de withacnistina para el tratamiento del cáncer". - Google Patents
"compuestos de withacnistina para el tratamiento del cáncer".Info
- Publication number
- CR10225A CR10225A CR10225A CR10225A CR10225A CR 10225 A CR10225 A CR 10225A CR 10225 A CR10225 A CR 10225A CR 10225 A CR10225 A CR 10225A CR 10225 A CR10225 A CR 10225A
- Authority
- CR
- Costa Rica
- Prior art keywords
- withacnistine
- compounds
- relates
- present
- cancer treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere al tratamiento de tumores y tejidos cancerosos y a la prevención de la tumorigénesis y la transformación maligna a través de la modulación de la señalización intracelular de STAT3. La presente invención se refiere a composiciones farmacéuticas que contienen uno o más compuestos de withacnistina, o una de sus sales o derivados aceptables para uso farmacéutico. En una forma de realización, la presente invención se refiere a una composición que comprende una mezcla de withacnistina , 3-metoxi-2,3-dihidrowithacnistina, y 3-etoxi-2,3-dihidrowithacnistina, o una sal o derivado de cualquiera de los anteriores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76493606P | 2006-02-02 | 2006-02-02 | |
US78121306P | 2006-03-10 | 2006-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10225A true CR10225A (es) | 2009-01-09 |
Family
ID=38345662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10225A CR10225A (es) | 2006-02-02 | 2008-08-20 | "compuestos de withacnistina para el tratamiento del cáncer". |
Country Status (5)
Country | Link |
---|---|
US (2) | US20070191490A1 (es) |
EP (1) | EP1986656A4 (es) |
CA (1) | CA2641262A1 (es) |
CR (1) | CR10225A (es) |
WO (1) | WO2007092278A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2050458A1 (en) * | 2007-10-17 | 2009-04-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL24 for inducing hyperproliferative or autoimmune cell death |
KR20110033922A (ko) | 2008-07-08 | 2011-04-01 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 전사의 신호 변환자 및 활성제(stats)의 증식 및 활성화의 신규한 억제제 |
US20120238532A1 (en) * | 2009-11-30 | 2012-09-20 | Cedars-Sinai Medical Center | Treatment of human osteosarcoma |
US9238069B2 (en) * | 2009-12-16 | 2016-01-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment |
CN104023760A (zh) * | 2011-10-28 | 2014-09-03 | 普莱萨格生命科学公司 | 药物递送方法 |
CN109528749B (zh) * | 2017-09-22 | 2023-04-28 | 上海交通大学医学院附属瑞金医院 | 长链非编码rna-h19在制备治疗垂体瘤药物中的用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4867978A (en) * | 1987-03-27 | 1989-09-19 | Joseph Gold | Method of prolonging cancerous patient survival in humans with hydrazine sulfate |
US4921963A (en) * | 1987-04-13 | 1990-05-01 | British Columbia Cancer Foundation | Platinum complexes with one radiosensitizing ligand |
US5681950A (en) * | 1994-09-28 | 1997-10-28 | Universidad De Antioquia | Withajardins |
US5962527A (en) * | 1995-03-21 | 1999-10-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating cancers |
AU6407696A (en) * | 1995-07-07 | 1997-02-10 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Method of identifying inhibitors of the jak-stat signal transduction pathway |
US5925356A (en) * | 1996-07-09 | 1999-07-20 | Subbiah; Ven | Method of isolating cucurbitacin |
US5683698A (en) * | 1996-08-02 | 1997-11-04 | New England Deaconess Hospital | Formulation for alleviating symptoms associated with arthritis |
AU7980098A (en) * | 1997-06-20 | 1999-01-04 | Elena Y. Enioutina | Method to enhance innate immunity defense mechanisms by treatment with plan t-derived alkaloids |
US6299869B1 (en) * | 1997-12-08 | 2001-10-09 | Genentech, Inc. | Human interferon-epsilon: a type I interferon |
US20020103386A1 (en) * | 1999-10-14 | 2002-08-01 | Therezinha C. B. Tomassini | Process for isolating physalins from plants and pharmaceutical compositions containing physalins |
US6403830B2 (en) * | 2000-03-24 | 2002-06-11 | Pharmacia Corporation | Amidino compound and salts thereof useful as nitric oxide synthase inhibitors |
US7157438B2 (en) * | 2001-06-16 | 2007-01-02 | University Of South Florida Board Of Trustees | Rhob as a suppressor of cancer cell growth and cell transformation |
US6531645B1 (en) * | 2000-11-08 | 2003-03-11 | University Of South Florida | RAS/P21 transgenic mouse |
AU2002307217A1 (en) * | 2001-03-28 | 2002-10-15 | University Of South Florida | Materials and methods for treatment of cancer and identification of anti-cancer compounds |
US20050049299A1 (en) * | 2003-08-26 | 2005-03-03 | Aggarwal Bharat B. | Selective inhibitors of stat-3 activation and uses thereof |
US7108870B2 (en) * | 2004-04-13 | 2006-09-19 | Council Of Scientific & Industrial Research | Process for isolation of withaferin-A from plant materials and products therefrom |
US7807662B2 (en) * | 2004-12-23 | 2010-10-05 | University Of South Florida | Platinum IV complex inhibitor |
-
2007
- 2007-02-02 CA CA002641262A patent/CA2641262A1/en not_active Abandoned
- 2007-02-02 WO PCT/US2007/002827 patent/WO2007092278A2/en active Application Filing
- 2007-02-02 EP EP07763535A patent/EP1986656A4/en not_active Withdrawn
- 2007-02-02 US US11/701,722 patent/US20070191490A1/en not_active Abandoned
-
2008
- 2008-08-20 CR CR10225A patent/CR10225A/es not_active Application Discontinuation
-
2016
- 2016-12-02 US US15/367,917 patent/US20170173049A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2641262A1 (en) | 2007-08-16 |
US20070191490A1 (en) | 2007-08-16 |
US20170173049A1 (en) | 2017-06-22 |
EP1986656A4 (en) | 2012-05-16 |
WO2007092278A2 (en) | 2007-08-16 |
WO2007092278A3 (en) | 2007-12-06 |
EP1986656A2 (en) | 2008-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2012003680A1 (es) | Compuestos derivados de (1,8) naftiridinas 2,4 diaril sustituidas inhibidores de quinasas; su procedimiento de obtencion; composicion farmaceutica; y su uso para el tratamiento y/o prevencion de cancer, tumor, tumores malignos, entre otros; kit farmaceutico. | |
CR10225A (es) | "compuestos de withacnistina para el tratamiento del cáncer". | |
CY1119217T1 (el) | Ενωση για την αγωγη του καρκινου | |
CL2008000020A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos. | |
CL2018002787A1 (es) | Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. | |
CR11099A (es) | Uso de compuestos inhibidores de quinaxolina de p13k-alfa para el tratamiento del cancer | |
UY31384A1 (es) | Novedosos compuestos heterociclicos para la inhibicion de la proteina quinasa b | |
NI201100130A (es) | Derivados de pirimidin indol para el tratamiento de cáncer. | |
DOP2009000159A (es) | Inhibidores de la poli(adp-ribosa) polimerasa | |
CL2012003503A1 (es) | Compuestos derivados de morfolin pirimidinas sustituidos, inhibidores de la proteina quinasa atr; composicion farmaceutica, utiles para la prevencion o el tratamiento de tumores cancerigenos. | |
CY1111721T1 (el) | Ακυλαμινοπυραζολια ως αναστολεις fgfr | |
ECSP109953A (es) | Derivados de piridazinona | |
UY31215A1 (es) | Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia. | |
GT201100017A (es) | Derivados de piridazina como inhibidores de smo | |
UY29360A1 (es) | Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones. | |
CR11100A (es) | Uso de inhibidores de piridopirimidinona de p13k-alfa en el tratamiento del cancer | |
UY29886A1 (es) | Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones | |
CL2008001743A1 (es) | Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende. | |
ECSP088306A (es) | Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr | |
AR062402A1 (es) | Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento del cancer de piel | |
SV2009003389A (es) | Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer | |
DOP2009000200A (es) | Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pimiridina como inhibidores hsp-90 para tratar el cancer | |
BRPI0906444A8 (pt) | compostos de 4-piridinona e seu uso para câncer | |
AR078613A1 (es) | Derivados de sulfoxidos benzooxazolicos y benzotriazolicos inhibidores de autotaxinas, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores. | |
CR20120171A (es) | Uso de n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi) fenil)-4-(4-metil-2-tienil)-1-ftalazinamina en el tratamiento de cáncer resistente al agente antimitótico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |